Nahid A. Qushmaq: Advancing Anticoagulation Through Factor XI/XIa Inhibition
Nahid A. Qushmaq, General Supervisor Assistant for Medical Support Services, Consultant Adult Hematology of Thrombosis and Hemostasis, Head Of Research and Development Department at King Abdullah Medical Complex – Jeddah, shared a post on LinkedIn:
“One of the most valuable sessions I attended at ISTH 2026 was ‘Emerging Therapies in Thrombosis: Factor XI/XIa Inhibitors’, delivered by Dr. Jeffrey Weitz.
The session provided an excellent overview of the evolving role of FXI/FXIa inhibition in thrombosis prevention and highlighted the exciting potential of these novel agents to reduce thrombotic events while minimizing bleeding risk, making it one of the most promising next-generation anticoagulant strategies.
An insightful and thought-provoking session that reinforces how rapidly the field of thrombosis is advancing.”

Stay updates with Hemostasis Today.
-
Nov 17, 2026, 01:27X. Long Zheng: Optimizing Treatment in Immune TTP
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C